Evidence map›Paper›PMID 38603667›Full record

ArticlePloS one2024

Serum Nostrin-A risk factor of death, kidney replacement therapy and acute kidney disease in acute kidney injury.

Stefan Erfurt, Martin Lauxmann, Katharina Asmus, Stefanie Oess, Daniel Patschan, Meike Hoffmeister

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07637435 (The Role of Vascular Endothelial Markers in Predicting Renal Function Prognosis and Mortality in Patients Undergoing Emergency Hemodialysis Due to Acute Kidney Injury), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07637435 nacompletednot on this mapstarted 2025, after this paper: background citation

The Role of Vascular Endothelial Markers in Predicting Renal Function Prognosis and Mortality in Patients Undergoing Emergency Hemodialysis Due to Acute Kidney Injury

TypeinterventionalSponsorMuğla Sıtkı Koçman UniversityRan2025 to 2025Enrolled170ConditionsAcute Kidney Injury, HemodialysisArmsSerum samples before hemodialysis.
3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Stefan ErfurtBrandenburg Medical School Theodor Fontane, Institute of Biochemistry, Brandenburg an der Havel, Germany.ORCID 0000-0001-8892-1805
Martin LauxmannBrandenburg Medical School Theodor Fontane, Institute of Biochemistry, Brandenburg an der Havel, Germany.
Katharina AsmusDepartment of Internal Medicine I-Cardiology, Nephrology and Internal Intensive Medicine, Brandenburg University Hospital, Brandenburg Medical School Theodor Fontane, Brandenburg an der Havel, Germany.
Stefanie OessBrandenburg Medical School Theodor Fontane, Institute of Biochemistry, Brandenburg an der Havel, Germany.
Daniel PatschanDepartment of Internal Medicine I-Cardiology, Nephrology and Internal Intensive Medicine, Brandenburg University Hospital, Brandenburg Medical School Theodor Fontane, Brandenburg an der Havel, Germany.
Meike HoffmeisterBrandenburg Medical School Theodor Fontane, Institute of Biochemistry, Brandenburg an der Havel, Germany.ORCID 0000-0003-3561-5286

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe prediction of Acute Kidney Injury (AKI)-related outcomes remains challenging. Persistent kidney excretory dysfunction for longer than 7 days has been defined as Acute Kidney Disease (AKD). In this study, we prospectively quantified serum Nostrin, an essential regulator of endothelial NO metabolism, in hospitalized patients with AKI. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: In-hospital subjects with AKI of various etiology were identified through the in-hospital AKI alert system of the Brandenburg University Hospital. Serum Nostrin, and serum NGAL and KIM-1 were measured within a maximum of 48 hours from the timepoint of initial diagnosis of AKI. The following endpoints were defined: in-hospital death, need of kidney replacement therapy (KRT), recovery of kidney function (ROKF) until discharge.

resultsAKI patients had significantly higher serum Nostrin levels compared to Controls. The level of serum Nostrin increased significantly with the severity of AKI. Within the group of AKI patients (n = 150) the in-hospital mortality was 16.7%, KRT was performed in 39.3%, no ROKF occurred in 28%. Patients who required KRT had significantly higher levels of serum Nostrin compared to patients who did not require KRT. Significantly higher levels of serum Nostrin were also detected in AKI patients without ROKF compared to patients with ROKF. In addition, low serum Nostrin levels at the timepoint of AKI diagnosis were predictive of in-hospital survival. For comparison, the serum concentrations of NGAL and KIM-1 were determined in parallel to the Nostrin concentrations and the results confirm the prognostic properties of serum Nostrin in AKI.

conclusionsThe current study suggests serum Nostrin as novel biomarker of AKI-associated mortality, KRT and Acute Kidney Disease.

Indexed as

Acute Kidney InjuryAcute DiseaseBiomarkersHospital MortalityHumansLipocalin-2Renal Replacement TherapyRisk FactorsBiomarkersLipocalin-2

Identifiers

PMID38603667
PMCPMC11008819

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.